We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HSIC icon
76
Henry Schein
HSIC
$10B
$4.37M 0.28%
65,494
– –
HZNP
77
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.34M 0.28%
221,678
+30,100
+16% +$572K
ESRX
78
DELISTED
Express Scripts Holding Company
ESRX
$4.23M 0.27%
44,500
– –
XRAY icon
79
Dentsply Sirona
XRAY
$2.81B
$4.18M 0.27%
110,878
+35,785
+48% +$1.49M
TNDM icon
80
Tandem Diabetes Care
TNDM
$1.17B
$4.16M 0.26%
97,195
-16,811
-15% -$587K
INSP icon
81
Inspire Medical Systems
INSP
$1.46B
$3.82M 0.24%
90,696
+42,743
+89% +$2.01M
CERN
82
DELISTED
Cerner Corp
CERN
$3.81M 0.24%
59,146
+1,246
+2% +$79.3K
ENDP
83
DELISTED
Endo International plc
ENDP
$3.66M 0.23%
217,392
+118,300
+119% +$1.68M
SGEN
84
DELISTED
Seagen Inc. Common Stock
SGEN
$3.62M 0.23%
46,950
-2,550
-5% -$188K
INCY icon
85
Incyte
INCY
$23.4B
$3.62M 0.23%
52,350
-2,500
-5% -$172K
OXFD
86
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.6M 0.23%
221,837
+111,176
+100% +$1.59M
STIM icon
87
Neuronetics
STIM
$113M
$3.59M 0.23%
111,907
+61,907
+124% +$1.88M
CHRS icon
88
Coherus Oncology
CHRS
$216M
$3.56M 0.23%
215,935
+18,100
+9% +$321K
VEEV icon
89
Veeva Systems
VEEV
$31.7B
$3.56M 0.23%
32,691
+22,395
+218% +$2.03M
IBB icon
90
iShares Biotechnology ETF
IBB
$9.23B
$3.41M 0.22%
+28,000
New +$3.3M
NKTR icon
91
Nektar Therapeutics
NKTR
$2.31B
$3.38M 0.21%
3,701
+1,401
+61% +$1.2M
AMED
92
DELISTED
Amedisys
AMED
$3.15M 0.2%
+25,204
New +$2.78M
LGND icon
93
Ligand Pharmaceuticals
LGND
$6.08B
$3.09M 0.2%
18,066
-1,282
-7% -$193K
ICPT
94
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.05M 0.19%
24,148
-500
-2% -$52.9K
MTLS
95
Materialise
MTLS
$379M
$2.91M 0.18%
210,731
+171,402
+436% +$2.32M
PEN icon
96
Penumbra
PEN
$12.5B
$2.87M 0.18%
19,142
+5,115
+36% +$716K
JNJ icon
97
Johnson & Johnson
JNJ
$609B
$2.76M 0.18%
20,000
– –
MDSO
98
DELISTED
Medidata Solutions, Inc.
MDSO
$2.71M 0.17%
36,907
+32,258
+694% +$2.58M
AGN
99
DELISTED
Allergan plc
AGN
$2.48M 0.16%
13,000
+3,000
+30% +$551K
RARE icon
100
Ultragenyx Pharmaceutical
RARE
$2.88B
$2.43M 0.15%
31,850
-7,300
-19% -$594K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.